Clinical Trial Search

Primary: Rate of Investigator Confirmed Hereditary Angioedema (HAE) Attacks During Treatment Period — 1.967; 0.480; 0.526; 0.257 Attacks per 4 weeks — p=<0.001

Primary: Percentage of Participants Who Discontinued Study Treatment During the Induction Period Due to Treatment Emergent Adverse Events (TEAEs). — 27 Percentage of Participants

Primary: Number of Participants With Neurologic Injury — 45; 19 Participants — p=0.1444

Primary: Percentage of Subjects With at Least One Treatment-emergent Adverse Event (TEAE) During the Evaluation Period From Entry Visit 1 Through End of Treatment (up to 9 Years)…

Primary: 6 Month Progression-Free Survival — 69 percentage of participants

Primary: Percent Change in Lumbar Spine Bone Mineral Density (BMD) From Baseline to 48 Weeks — -4.0; -3.1; -0.6 percent change

Primary: Medication Side Effects Score — 9.5; 6.2; 6.4; 4.1 Score on a scale

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 7.2; 9.5 percent improvement — p=0.2735

Primary: Latency to Initiate Ad-lib Smoking Session — 28.134; 45.861; 21.737 minutes

Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants

Primary: All Cause Mortality — 8 Participants

Primary: Feasibility Benchmark: Number of Parents That Complete the Memory Aid 1. — 35 Participants

Primary: Pathologic Complete Response — 26 percentage of participants

Primary: Percent Improvement From Baseline In Mean NRS Average Pain At End Of Treatment — 10.7; 4.5 percent improvement — p=0.0854

Primary: Percentage of Participants Defined by "Excellent" or "Good" in the Aronchick Scale — 50; 87.5; 81.3; 81.3 percentage of participants